Transarterial Microembolization Therapy for Chronic First Metatarsophalangeal Joint Pain
🔍 **Clinical Question:**
To evaluate the association between tumor-absorbed dose (TAD) relative to response and survival among patients with breast cancer liver metastasis (BCLM) treated with yttrium-90 (90Y) transarterial radioembolization (TARE).
💡 **Key Insight:**
Overall survival was found to be significantly improved in responders compared with nonresponders among patients with breast cancer liver metastasis treated with yttrium-90 glass microspheres.
Tumor-absorbed dose showed a significant survival advantage above 145 Gy.
No significant difference was found in tumor-absorbed dose between responders and nonresponders.
👉 **Why it matters:**
Metabolic response predicts survival, dose thresholds matter, and higher dose alone does not guarantee response. These results highlight the need for personalized dosimetry in 90Y therapy for breast cancer liver metastases.
➡️ **Full Article:**
https://doi.org/10.1016/j.jvir.2025.08.045
#InterventionalRadiology #IO #TARE #SIRT #Y90 #BreastCancer #TumorBoard #MedEd
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.